bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company is headquartered in Craponne, Auvergne-Rhone-Alpes and currently employs 14,754 full-time employees. The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Follow-Up Questions
BMXMF 주식의 가격 성능은 어떻습니까?
BMXMF의 현재 가격은 $134.24이며, 전 거래일에 decreased 0% 하였습니다.
Biomerieux SA의 주요 사업 주제나 업종은 무엇입니까?
Biomerieux SA은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Biomerieux SA의 시가총액은 얼마입니까?
Biomerieux SA의 현재 시가총액은 $15.8B입니다
Biomerieux SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 16명의 분석가가 Biomerieux SA에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 9명의 매수, 6명의 보유, 1명의 매도, 그리고 2명의 강력한 매도를 포함합니다